We are live on ! Find out more
KYTH

KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH

Delisted

KYTH was delisted on the 30th of September, 2015.

110 hedge funds and large institutions have $631M invested in KYTHERA BIOPHARMACEUTICALS, INC COM in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 45 increasing their positions, 32 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

41% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 32

6% more funds holding

Funds holding: 104110 (+6)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

12% less capital invested

Capital invested by funds: $713M → $631M (-$82.1M)

97% less call options, than puts

Call options by funds: $66K | Put options by funds: $2.05M

Holders
110
Holders Change
+6
Holders Change %
+5.77%
% of All Funds
3.19%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
45
Reduced
32
Closed
9
Calls
$66K
Puts
$2.05M
Net Calls
-$1.99M
Net Calls Change
-$680K
Name Holding Trade Value Shares
Change
Change in
Stake
AAM
26
Aureus Asset Management
Massachusetts
$4.56M -$478K -13,570 -9%
JP Morgan Chase
27
JP Morgan Chase
New York
$4.3M +$42K +1,193 +0.9%
CWG
28
C WorldWide Group
Denmark
$4.24M +$4.48M +127,100 New
TCM
29
Tekla Capital Management
Massachusetts
$3.65M +$2.2M +62,433 +127%
Allianz Asset Management
30
Allianz Asset Management
Germany
$3.5M
TAM
31
Tocqueville Asset Management
New York
$3.26M +$215K +6,095 +7%
Lord, Abbett & Co
32
Lord, Abbett & Co
New Jersey
$3.01M -$1.63M -46,347 -34%
AC
33
Ascend Capital
California
$2.9M +$44.4K +1,262 +1%
BNP Paribas Asset Management
34
BNP Paribas Asset Management
France
$2.85M +$179K +5,073 +6%
Geode Capital Management
35
Geode Capital Management
Massachusetts
$2.85M +$36.2K +1,029 +1%
GC
36
Guggenheim Capital
Illinois
$2.29M +$387K +10,999 +19%
RHJA
37
Rice Hall James & Associates
California
$2.18M +$1.34M +38,070 +134%
SAM
38
Senzar Asset Management
New York
$2.17M -$2.06M -58,600 -47%
EAM
39
Eagle Asset Management
Florida
$2.15M -$167K -4,728 -7%
TCIM
40
TIAA CREF Investment Management
New York
$2.13M -$20.3K -575 -0.9%
AC
41
Amici Capital
New York
$1.76M +$271K +7,700 +17%
SM
42
Senvest Management
New York
$1.73M +$1.86M +52,787 New
BIM
43
BlackRock Investment Management
Delaware
$1.66M +$15.3K +434 +0.9%
BCM
44
BBT Capital Management
Texas
$1.64M
Deutsche Bank
45
Deutsche Bank
Germany
$1.58M +$1.32M +37,472 +342%
AP
46
AlpInvest Partners
Netherlands
$1.57M +$522K +14,816 +45%
Charles Schwab
47
Charles Schwab
California
$1.54M +$315K +8,941 +24%
MAA
48
Managed Account Advisors
New Jersey
$1.47M +$48K +1,363 +3%
OAM
49
Oxford Asset Management
United Kingdom
$1.45M +$1.17M +33,340 +321%
RJA
50
Raymond James & Associates
Florida
$1.37M +$112K +3,167 +8%

KYTH Hedge Fund Activity: Q3 2014 in Review

110 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) for Q3 2014, worth a combined $631M — down 12% from $713M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KYTH positions and 9 closed out — a net gain of 6 holders — while 45 added to existing stakes and 32 trimmed.

The largest buyer was Kornitzer Capital Management, adding an estimated $16.7M. The largest seller was Redmile Group, cutting an estimated $9.82M.

  • 110 institutional investors held KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) as of Q3 2014, up from 104 in Q2 2014.
  • Funds reported $631M of KYTHERA BIOPHARMACEUTICALS, INC COM stock for Q3 2014, down 12% quarter-over-quarter.
  • 15 funds opened new KYTHERA BIOPHARMACEUTICALS, INC COM positions in Q3 2014 and 9 closed out, a net change of +6 holders.
  • The largest KYTHERA BIOPHARMACEUTICALS, INC COM buyer in Q3 2014 was Kornitzer Capital Management, an estimated $16.7M added.
  • The largest KYTHERA BIOPHARMACEUTICALS, INC COM seller in Q3 2014 was Redmile Group, an estimated $9.82M sold.

Based on aggregated 13F filings for Q3 2014.